Article

Court denies bid to reclassify dry eye drug

Washington, DC—A court has ruled that FDA classification of Allergan's cyclosporine ophthalmic emulsion 0.05% (Restasis) as an antibiotic is supported by the FDA's Modernization Act of 1997. The U.S. District Court for the District of Columbia dismissed Allergan's lawsuit seeking to reclassify cyclosporine as a non-antibiotic.

Washington, DC-A court has ruled that FDA classification of Allergan's cyclosporine ophthalmic emulsion 0.05% (Restasis) as an antibiotic is supported by the FDA's Modernization Act of 1997. The U.S. District Court for the District of Columbia dismissed Allergan's lawsuit seeking to reclassify cyclosporine as a non-antibiotic.

Allergan brought the lawsuit in October 2003 to have the FDA reclassify and to obtain the certainty of 3 years of marketing exclusivity under the Hatch-Waxman Act.

Allergan believes the ruling will have a limited effect on the marketing of Restasis because it has a solid patent estate covering Restasis, with a use patent that does not expire until August 2009 and a formulation patent that does not expire until May 2014. Allergan said it brought the lawsuit to augment its patent estate with the certainty of 3 years of Hatch-Waxman exclusivity. Because Restasis was approved by the FDA in December 2002, however, such marketing exclusivity would have expired in December 2005.

"Allergan has spent considerable effort developing the first FDA-approved dry eye medication-Restasis-and we had hoped to have been rewarded for our technological innovation with Hatch-Waxman marketing exclusivity," said Douglas S. Ingram, Allergan's executive vice president, general counsel, and secretary. "Fortunately, Restasis has intellectual property protection through a patent estate that extends until May 2014 and thus there should be no practical need for separate Hatch-Waxman marketing exclusivity."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.